December 18, 2024 – Talk Bio

Actionable Insights Powered by AI

Merck Enters Obesity Market with $2 Billion Deal for Chinese Oral GLP-1 Drug

4 months ago talkbio0Tagged Benefit, cardiometabolic, Glucagon-Like Peptide 1, Hansoh Pharma, HS-10535, Merck, Obesity, Oral cavity, Weight Loss

Merck, Obesity, Oral GLP-1, Hansoh Pharma, HS-10535, Weight Loss, Cardiometabolic Benefits

Biopharma’s New Horizon: Industry Leaders Converge at JPM 2025

4 months ago talkbio0Tagged Biopharma, Biotechnology, Clustered Regularly Interspaced Short Palindromic Repeats, Doudna, Drug Industry, Gene Modification, Health care facility, healthcare, Janet, Jennifer, JPM, Robert Nelsen, Woodcock

JPM 2025, Biopharma, Jennifer Doudna, Janet Woodcock, Robert Nelsen, Scott Gottlieb, Healthcare, Gene Editing, CRISPR, Pharmaceutical Industry, Biotechnology

Novo Holdings Spearheads $100M Series C Financing for SiteOne Therapeutics to Develop Non-Opioid Pain Therapies

4 months ago talkbio0Tagged Holdings, ion channel modulators, Non-Opioid Pain, Opioid Epidemic, pain chronic management, Peripheral Nervous System, Series C financing, SiteOne Therapeutics

Novo Holdings, SiteOne Therapeutics, Non-opioid pain treatments, Series C financing, Ion channel modulators, Peripheral nervous system (PNS) pain treatments, Chronic pain management, Opioid epidemic

Regeneron’s EYLEA HD Succeeds in Phase 3 Trial for Retinal Vein Occlusion, Paving Way for 2025 FDA Submission

4 months ago talkbio0Tagged aflibercept, dosing, Extension, Eylea, Hodgkin Disease, Interval, Phase 3 QUASAR trial, Regeneron, Retinal Vein Occlusion, Submission, United States Food and Drug Administration

EYLEA HD, Aflibercept, Retinal Vein Occlusion (RVO), Phase 3 QUASAR Trial, Extended Dosing Intervals, FDA Submission 2025, Regeneron Pharmaceuticals

EU Regulator to Investigate Potential Link Between Ozempic and Rare Eye Condition NAION

4 months ago talkbio0Tagged Agencies, Diabetes, European (ethnic group), Evaluation, NAION, Nordisk, Ozempic, semaglutide

Ozempic, NAION, European Medicines Agency, Novo Nordisk, semaglutide, eye disorder, diabetes drug, investigation

Aurion Biotech’s AURN001 Shows Significant Vision Improvement in Phase 1/2 Trial for Corneal Edema

4 months ago talkbio0Tagged allogeneic cell therapy, AURN001, Clinical Trials, Corneal edema, Corneal endothelial dysfunction, Regenerative Medicine

AURN001, corneal edema, corneal endothelial dysfunction, allogeneic cell therapy, regenerative medicine, clinical trial results

Candid Therapeutics Expands T-Cell Engager Pipeline with Strategic Collaborations

4 months ago talkbio0Tagged Autoimmune Diseases, Biotechnology, biotherapeutics, Candid, Collaboration, engagers, Nona Biosciences, T-Lymphocyte

T-cell engagers, autoimmune diseases, biotechnology, Candid Therapeutics, collaborations, EpimAb Biotherapeutics, Nona Biosciences

Roche Discontinues Second Hemophilia A Gene Therapy Candidate Under Spark Amid Shift in Hematologic Portfolio

4 months ago talkbio0Tagged gene therapy, Hemlibra, Hemophilia A, Roche (company)

Roche, Spark Therapeutics, Hemophilia A, Gene Therapy, RG6358, SPK-8016, Hemlibra, SPK-8011

Regeneron and Bayer Achieve Phase III Success with High-Dose Eylea for Retinal Vein Occlusion, Paving Way for Label Expansion

4 months ago talkbio0Tagged Bayer, Biosimilars, competition, expansion, Eylea HD, Macular retinal edema, Phase 3 Clinical Trials, Regeneron, Retinal Vein Occlusion

Regeneron, Bayer, Eylea HD, Retinal Vein Occlusion (RVO), Macular Edema, Phase III Trial, Label Expansion, Biosimilar Competition

Sandoz Reaches $275 Million Settlement in US Generic Drug Price Fixing Case

4 months ago talkbio0Tagged Antitrust, Drug Industry, drug price fixing, Litigation, sandoz, settlement

Sandoz, generic drug price fixing, settlement, antitrust litigation, pharmaceutical industry